These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22577718)

  • 21. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.
    Lucidarme N; Ruiz JC; Czernichow P; Léger J
    J Pediatr; 2000 Jul; 137(1):56-62. PubMed ID: 10891822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density trends in Indian patients with hyperthyroidism--effect of antithyroid therapy.
    Dhanwal DK; Gupta N
    J Assoc Physicians India; 2011 Sep; 59():561-2, 567. PubMed ID: 22334969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study.
    Braith RW; Conner JA; Fulton MN; Lisor CF; Casey DP; Howe KS; Baz MA
    J Heart Lung Transplant; 2007 Feb; 26(2):132-7. PubMed ID: 17258146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
    Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
    J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
    Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
    Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
    Bianchi ML; Cimaz R; Bardare M; Zulian F; Lepore L; Boncompagni A; Galbiati E; Corona F; Luisetto G; Giuntini D; Picco P; Brandi ML; Falcini F
    Arthritis Rheum; 2000 Sep; 43(9):1960-6. PubMed ID: 11014345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
    Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
    Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to alendronate in osteoporosis after previous treatment with etidronate.
    Fairney A; Kyd P; Thomas E; Wilson J
    Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
    Golden NH; Iglesias EA; Jacobson MS; Carey D; Meyer W; Schebendach J; Hertz S; Shenker IR
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3179-85. PubMed ID: 15784715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
    J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
    Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
    Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
    Arrabal-Polo MA; Arias-Santiago S; de Haro-Muñoz T; Lopez-Ruiz A; Orgaz-Molina J; Gonzalez-Torres S; Zuluaga-Gomez A; Arrabal-Martin M
    Urology; 2013 Apr; 81(4):731-7. PubMed ID: 23375914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
    Heervä E; Huilaja L; Leinonen P; Peltonen S; Peltonen J
    Calcif Tissue Int; 2014 Jun; 94(6):608-12. PubMed ID: 24390519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period.
    Rizi MM; Salari A; Salesi M; Rasooli L; Karimifar M
    Clin Rheumatol; 2024 Apr; 43(4):1375-1379. PubMed ID: 38347325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.